Axatilimab + CAR-T for Lymphoma

JM
CG
Overseen ByCaitlin Guzowski, MBA, MHA, CCRC
Age: Any Age
Sex: Any
Trial Phase: Phase 1
Sponsor: Northside Hospital, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Axatilimab + CAR-T in High-Risk Lymphoma

Are You a Good Fit for This Trial?

This trial is for adults (18+) with confirmed large B-cell lymphoma who have high-risk features and are eligible for CAR-T therapy. Participants must have measurable disease, good heart, liver, lung, and kidney function.

Inclusion Criteria

I am 18 years old or older.
Calculated or measured creatinine Clearance ≥ 30 mL/min
ALT/AST < 5x ULN
See 8 more

Exclusion Criteria

I currently have hepatitis B or C infection.
I am unable to care for myself and need help with daily activities.
I have not had another aggressive cancer in the past 3 years.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive axatilimab in combination with CAR T cell therapy, following a fast-track dose escalation design

1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at multiple timepoints

1 year

What Are the Treatments Tested in This Trial?

Interventions

  • Axatilimab

Trial Overview

The study tests the combination of Axatilimab (an antibody drug) with CAR-T cell therapy in people with high-risk lymphoma to see if this approach works better than standard treatments.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Axatilimab + Commercial CAR T cell therapyExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Northside Hospital, Inc.

Lead Sponsor

Trials
26
Recruited
1,100+